Disc Medicine announces $200M common stock offering

Disc Medicine (IRON) announced that it has commenced an underwritten offering of $200M of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. Disc intends to use the net proceeds from the proposed offering to fund research and clinical development of its current or additional product candidates, to support the potential commercialization of bitopertin for erythropoietic protoporphyria and X-linked protoporphyria, as well as for working capital and other general corporate purposes. Jefferies, Leerink Partners, Stifel and Cantor are acting as joint book-running managers for the proposed offering.